Trial Profile
An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects With Covid-19 Infection in Addition to Standard of Care (SOC)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Apabetalone (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Resverlogix Corporation
- 14 Nov 2023 Status changed from recruiting to discontinued as the trial was unable to recruit subjects
- 17 Feb 2022 According to a Resverlogix Corporation media release,the first Brazilian site has been initiated for its Phase 2b study to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Additionally, the second Canadian site, in Calgary, Alberta, has also been initiated. A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon.
- 18 Jan 2022 According to a Resverlogix Corporation media release, additional Canadian sites in Calgary and Toronto will soon be coming online, as well as four new sites in Brazil, that will receive apabetalone supply this week